Bayesian Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bayesian Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$481K	Buy	+14,200	New	+$473K	0.31%	92
2024 Q3	–	Sell	-34,100	Closed	-$554K	–	1033
2024 Q2	$554K	Buy	+34,100	New	+$525K	0.06%	344
2023 Q2	–	Sell	-39,300	Closed	-$348K	–	1061
2023 Q1	$348K	Buy	+39,300	New	+$389K	0.04%	474
2022 Q3	–	Sell	-36,900	Closed	-$277K	–	1012
2022 Q2	$277K	Sell	36,900 -41,600	-53%	-$362K	0.05%	507
2022 Q1	$737K	Buy	+78,500	New	+$655K	0.11%	274
2021 Q2	–	Sell	-31,700	Closed	-$366K	–	638
2021 Q1	$366K	Sell	31,700 -92,000	-74%	-$1.05M	0.08%	303
2020 Q4	$1.19M	Sell	123,700 -7,600	-6%	-$72.8K	0.31%	81
2020 Q3	$1.18M	Buy	131,300 +70,300	+115%	+$744K	0.29%	85
2020 Q2	$752K	Sell	61,000 -90,200	-60%	-$1.02M	0.17%	174
2020 Q1	$1.36M	Buy	+151,200	New	+$1.55M	0.29%	76
2018 Q4	–	Sell	-53,100	Closed	-$1.14M	–	783
2018 Q3	$1.14M	Buy	+53,100	New	+$1.23M	0.19%	149
2017 Q2	–	Sell	-14,000	Closed	-$449K	–	591
2017 Q1	$449K	Buy	+14,000	New	+$478K	0.21%	185
2016 Q4	–	Sell	-24,655	Closed	-$1.13M	–	703
2016 Q3	$1.13M	Buy	24,655 +10,455	+74%	+$545K	0.74%	15
2016 Q2	$713K	Buy	+14,200	New	+$756K	0.43%	58

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Bayesian Capital Management's TEVA Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 14,200 shares worth $481K. The stake represents 0.31% of the portfolio and ranks #92 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in TEVA as recently as Q2 2024.

Bayesian Capital Management first reported a position in TEVA in Q2 2016 and has held it in 14 quarters since. The position peaked at $1.36M in Q1 2020. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Bayesian Capital Management held 14,200 shares of Teva Pharmaceuticals worth $481K as of Q2 2026.
Teva Pharmaceuticals was a new Bayesian Capital Management position in Q2 2026.
Teva Pharmaceuticals made up 0.31% of Bayesian Capital Management's portfolio in Q2 2026, its #92 holding.
Bayesian Capital Management first reported a position in Teva Pharmaceuticals in Q2 2016 and has held it in 14 quarters since.
Bayesian Capital Management's Teva Pharmaceuticals position peaked at $1.36M in Q1 2020.
675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.